PATRICK APILADO: Open Payments
NPI 1982114070 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,191 in 150 payments from 15 companies in 2025. Trend: 2023 $3,451 · 2024 $3,426 · 2025 $3,191
Food & beverage: $3,081Education: $110
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 36 | $681 |
| E.R. Squibb & Sons, L.L.C. | 23 | $435 |
| Alkermes, Inc. | 19 | $341 |
| Teva Pharmaceuticals USA, Inc. | 8 | $301 |
| Neurocrine BioSciences, Inc. | 14 | $288 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $283 |
| ABBVIE INC. | 9 | $251 |
| Vanda Pharmaceuticals Inc. | 6 | $178 |
| Janssen Pharmaceuticals, Inc | 8 | $172 |
| Axsome Therapeutics, Inc. | 4 | $91 |
Products named: REXULTI, COBENFY, ARISTADA, INGREZZA, CAPLYTA, VRAYLAR, FANAPT, SPRAVATO.
Industry payments across NV — which companies pay providers there.
